Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-05-04
2000-02-29
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514438, 514439, 514461, 514532, 549 66, 549 79, 549501, 554116, 560 11, 560 60, 560 61, 5483761, C07D23112, A61K 31215
Patent
active
060309938
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to 2-hydroxypropionic acid derivative expressed by the following formula (1), its manufacturing method and antidiabetic agent containing it. ##STR1## Wherein:
A is one selected from the radicals expressed by the following (i), (ii), (iii), (iv) and (v); ##STR2## R.sub.1 represents a lower alkyl; X represents hydroxy, mesylate, tosylate or bromine. alkoxy, lower alkyl, hydroxy, alkenyl, alkynyl, cyano or amino group; n denotes 0, 1 or 2).
BACKGROUND OF ART
The diabetic patients tend to suffer from some disorders such as inhibition of glucose uptake, inhibited glycolysis and increasing beta-oxidation of fatty acid in their peripheral tissues, which cause the use of fat for their body's energy source instead of glucose and lead to some diseases such as hyperglycemia, hyperlipidemia and hyperketonemia.
The beta-oxidation of fat in diabetic patients occurs in a mitochondrial substrate. Carnitine palmitoyl transferase I (CPT I) is an enzyme to transport a higher fatty acid from cytoplasm to a mitochondrial lo substrate, and plays an vital role in limiting the beta-oxidation rate.
Therefore, CPT I inhibitors will be utilized as an effective antidiabetic agent in that they may inhibit the beta-oxidation of higher fatty acids, increase the availability of glucose and exert the hypoglycemic, hypolipidemic and hypoketonemic effects.
The typical compounds belonging to the above mentioned CPT I inhibitors include palmoxirate, clomoxir(POCA) and etomoxir, and these compounds are characterized in that all of them have oxirane carboxylic acid in their most active site.
The inhibitory action of these oxirane carboxylic acid derivatives against the CPT I has yet to be elucidated up to now but it has been assumed that since these derivatives have the stable covalent bonding in the active sites of CPT I within cytoplasm, their inhibition action against the CPT I may contributed to the treatment of diabetes. Therefore, a possible mode of action is that when some nucleophilic substance at the active site of CPT I initiates to attack the epoxide ring structure of oxirane carboxylic acid derivatives, the opened epoxide ring forms a new hydroxyl group and at the same time, CPT I and oxirane carboxylic acid derivative is covalently bonded, thus inhibiting the CPT I activity.
However, the phase II clinical trials of etomoxir had been discontinued owing to some side effects associated with prolonged administration, such as enlarged heart and toxicity in the liver, but its cause has not been explicitly known up to now.
DISCLOSURE OF INVENTION
Based on the mechanism that these oxirane carboxylic acid derivatives have exerted inhibitory actions against the CPT I, the inventor et al. have extensively studied to develop some promising compounds with blood glucose lowering effects, thus showing remarkable antidiabetic activities and less side effects. To this end, the inventor et al. have come to know that as a result of screening various kinds of derivatives having oxirane carboxylic acid positioned at their most active sites, 2-hydroxypropionic acid derivative of the formula 1 with opened epoxy ring at oxirane structure has proven to have an excellent antidiabetic activity and less side effects. In consequence, this invention has been completed.
An object of this invention is to provide 2-hydroxypropionic acid derivative expressed by the following formula 1. ##STR3## Wherein: A is one selected from the radicals expressed by the following (i), (ii), (iii), (iv) and (v); ##STR4## R.sub.1 represents a lower alkyl; X represents hydroxy, mesylate, tosylate or bromine. (wherein; R.sub.2 .about.R.sub.17 represent independently hydrogen, halogen, alkoxy, lower alkyl, hydroxy, alkenyl, alkynyl, cyano or amino group; in particular, R.sub.2, R.sub.3, and R.sub.5 are hydrogen; R.sub.4 is hydrogen, chlorine or methoxy group; R.sub.7, R.sub.8 and R.sub.9 are hydrogen or chlorine; R.sub.10, R.sub.14, R.sub.15 and R.sub.17 are hydrogen or methyl group; R.sub.11, R.sub.12, R.sub.13 and R.sub.16 are preferably
REFERENCES:
patent: 4788306 (1988-11-01), Schieser et al.
R. Huber et al., Abstract No. 16547of, "Pharmacokinetics of the new antidiabetic drug Etomoxir in man after administration of the unlabeled or carbon-14-labeled compound", Chemical Abstracts, vol. 110, No. 19, p. 13, col. 1, (1989).
W. Ho et al., Abstract No. 18266h,"Alkylglycidic acids: potential new hypoglycemic agents", Chemical Abstracts, vol. 106, No. 3, p. 578, col. 2, (1987).
Cheong Jae Hoon
Chun Moon Woo
Huh Hoon
Jew Sang Sup
Jung Ki Hwa
Bak Kwang KIM
Geist Gary
Kwang Ho KO
Maier Leigh C.
Sang Sup JEW
LandOfFree
2-hydroxypropionic acid derivative and its manufacturing method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-hydroxypropionic acid derivative and its manufacturing method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-hydroxypropionic acid derivative and its manufacturing method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-683424